Retinoic acid receptor a agonists for the treatment of Alzheimer's disease (360G-Wellcome-084286_Z_07_C)
Retinoic acid receptor a agonists for the treatment of Alzheimer's disease. The current licensed treatments for Alzheimer's disease improve the symptoms that people experience but do not alter the progression of the underlying disease changes in the brain.Most of the attempts to develop new treatments have focused on altering deposits of the amyloid protein in the brain, but despite more than a decade of intensive research this has still not yielded any new therapies in the clinic. The studies of Dr Jonathan Corcoran of King's College London highlight a specific retinoic acid receptor (RAR)a agonist as a novel and exciting target for the development of new treatments. This agonist has two mechanisms of action - it regulates amyloid deposits in the brain and also plays a key role in the survival of neurons. In their project they will generate novel RARa agonists for the treatment of Alzheimer's disease.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 354795 |
Applicant Surname | Corcoran |
Approval Committee | Seeding Drug Discovery Committee |
Award Date | 2010-01-31T00:00:00+00:00 |
Financial Year | 2009/10 |
Grant Programme: Title | Seeding Drug Discovery Award |
Internal ID | 084286/Z/07/C |
Lead Applicant | Prof Jonathan Corcoran |
Partnership Value | 354795 |
Planned Dates: End Date | 2011-12-30T00:00:00+00:00 |
Planned Dates: Start Date | 2010-01-31T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | Greater London |